Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Johnson & Johnson Stock: After Last Year’s 50% Surge, Can the Momentum Continue?
Johnson & Johnson (JNJ) saw a significant surge in 2025 sales and anticipates hitting $100 billion in 2026, driven by a strategic pivot towards high-growth oncology and immunology segments and the exploration of a $20+ billion sale of DePuy Synthes. Despite strong growth in key products like TREMFYA and CARVYKTI, and institutional confidence through co-funding agreements, Wall Street’s mean price target suggests a potential near-term downside, although TIKR’s valuation model projects substantial long-term returns. The stock’s future hinges on successful product launches like ICOTYDE and management of ongoing talc litigation.